Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579455 | 0.91 | CYP4F2 (0.43) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL21644363 | 0.91 | CYP4F2 (0.46) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL8429950 | 0.88 | CYP4F2 (0.53) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL321594 | 0.87 | USP2 (0.49) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL10172533 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL2204005 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL18693034 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL237976 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL31726226 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL4975667 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-9187435-B2 | Bridged Spiro[2.4]heptane ester derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-11-17 | — | — | US | disclosed |
| EP-2640699-B1 | BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2387573-B1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B V (NL) | 2013-07-31 | — | — | EP | disclosed |
| EP-2387573-A1 | 6-PHENYL-LH-IMIDAZO Ý4, 5-C¨PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | N.V. Organon (NL) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253004-A1 | RAILCAR PRIMARY SUSPENSION | KAWASAKI JUKOGYO KABUSHIKI KAISHA (JP) | 2011-10-20 | — | — | US | disclosed |
| US-8026236-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-09-27 | — | — | US | disclosed |
| US-8026236-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-09-27 | — | — | US | disclosed |
| US-8026236-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-09-27 | — | — | US | disclosed |
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON | 2010-07-22 | — | — | US | disclosed |
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON | 2010-07-22 | — | — | US | disclosed |
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON | 2010-07-22 | — | — | US | disclosed |
| WO-2010081859-A1 | 6-PHENYL-LH-IMIDAZO [4, 5-C] PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | N.V. ORGANON (NL) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081859-A1 | 6-PHENYL-LH-IMIDAZO [4, 5-C] PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | N.V. ORGANON (NL) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSB | USP2 2264/4885SMN1; SMN2 4025/4885CYP4F2 2549/4885 |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | USP2 3720/4885SMN1; SMN2 1193/4885CYP4F2 2884/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | USP2 51/4885SMN1; SMN2 497/4885CYP4F2 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.